Trial Profile
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Zabinostat (Primary)
- Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Lung cancer; Lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- 17 Oct 2022 Status changed from active, no longer recruiting to completed.
- 07 Apr 2022 2-year survival of cancer patient treated with zabadinostat monotherapy results published in the Celleron Therapeutics Media Release
- 06 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.